This article is more than 5 years old. Information may no longer be current.

EyeGate reports increased net loss in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported a $3.823 million net loss for the second quarter of 2016, compared with a $1.541 million net loss in the second quarter of 2015.

The increased loss was primarily due to expenses related to clinical trials of EGP-437 for treatment of anterior uveitis and of EGP-437 for treatment of inflammation and pain after cataract surgery, as well as continued development of EyeGate Ocular Bandage Gel, according to a company press release.

Additionally, research and development expenses increased by $1.877 million to a total of $2.482 million over the second quarter of 2015. General and administrative expenses also increased to $1.579 million compared with $939,000 in the second quarter of 2015.